ASIA BYRD: Open Payments
NPI 1477321701 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,326 in 111 payments from 23 companies in 2025. Trend: 2023 $0 · 2024 $998 · 2025 $2,326
Food & beverage: $2,226Education: $100
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 34 | $351 |
| AstraZeneca Pharmaceuticals LP | 11 | $264 |
| HARMONY BIOSCIENCES LLC | 9 | $249 |
| ABBVIE INC. | 11 | $237 |
| Avadel CNS Pharmaceuticals, LLC | 5 | $186 |
| Inspire Medical Systems, Inc. | 1 | $125 |
| Merck Sharp & Dohme LLC | 3 | $92 |
| JAZZ PHARMACEUTICALS INC. | 3 | $86 |
| GENZYME CORPORATION | 4 | $81 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $76 |
Products named: NUCALA, LUMRYZ, WAKIX, TRELEGY ELLIPTA, DUPIXENT, DALVANCE, INSPIRE, BREZTRI.
Industry payments across IN — which companies pay providers there.
